Personalized Cannabidiol Delivery Systems

Publication ID: 24-11857678_0010_PTD
Published: October 28, 2025
Category:Future Evolutions & Paradigm Shifts

Legal Citation

pr1or.art Inc., “Personalized Cannabidiol Delivery Systems,” Published Technical Disclosure No. 24-11857678_0010_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857678_0010_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,678.

Summary of the Inventive Concept

A next-generation self-emulsifying cannabidiol technology integrating wearable devices, machine learning, and novel surfactant blends to optimize bioavailability, pharmacokinetics, and personalized treatment of neurological disorders.

Background and Problem Solved

The original patent disclosed self-emulsifying cannabidiol formulations, but limitations existed in terms of personalized delivery, bioavailability, and pharmacokinetics. The new inventive concept addresses these limitations by introducing wearable devices, machine learning algorithms, and novel surfactant blends to optimize cannabidiol treatment.

Detailed Description of the Inventive Concept

The inventive concept comprises a self-emulsifying cannabidiol composition, a wearable device for monitoring a subject's physiological response, and machine learning algorithms to predict optimal dosing regimens. The composition may include novel surfactant blends optimized for enhanced gut-brain axis interaction and administered via nasal spray or transdermal patch. A device for real-time monitoring of cannabidiol pharmacokinetics provides personalized dosing recommendations based on the subject's real-time cannabidiol levels. The inventive concept enables personalized treatment of neurological disorders, such as epilepsy, multiple sclerosis, and Parkinson's disease, in combination with neurostimulation therapies.

Novelty and Inventive Step

The new claims introduce wearable devices, machine learning algorithms, and novel surfactant blends, which are not obvious from the original patent. The integration of these components enables personalized cannabidiol delivery, optimized bioavailability, and real-time pharmacokinetics monitoring, making the inventive concept novel and non-obvious.

Alternative Embodiments and Variations

Alternative embodiments may include variations in wearable device design, machine learning algorithm implementation, and novel surfactant blend compositions. Additionally, the inventive concept could be adapted for use in veterinary medicine or for treating other diseases, such as cancer or inflammatory disorders.

Potential Commercial Applications and Market

The inventive concept has significant commercial potential in the pharmaceutical and biotechnology industries, particularly in the growing markets for personalized medicine and cannabidiol-based treatments. Target industries include pharmaceutical companies, biotech startups, and medical device manufacturers.

CPC Classifications

SectionClassGroup
A A61 A61K9/107
A A61 A61K9/4808
A A61 A61K9/4825
A A61 A61K31/05
A A61 A61K47/10
A A61 A61K47/14
A A61 A61K47/22

Field of Art

Pharmaceutical formulation and drug delivery systems, specifically focused on cannabinoid compositions, with expertise in emulsion technologies, surfactant design, and personalized medical delivery systems

Person of Ordinary Skill (PHOSITA) Profile

A pharmaceutical scientist or biomedical engineer with advanced degrees in pharmaceutical sciences, expertise in drug formulation, knowledge of emulsion technologies, familiarity with cannabinoid delivery mechanisms, and understanding of machine learning applications in personalized medicine

Obviousness Rationale

A person having ordinary skill in the art would recognize that the PTD's integration of wearable monitoring technology and machine learning with self-emulsifying cannabidiol compositions represents a predictable extension of existing pharmaceutical personalization strategies. The core cannabidiol formulation remains substantially similar to the source patent, with the primary innovations being the addition of monitoring and adaptive dosing technologies. These technological additions would be considered obvious improvements within the standard progression of pharmaceutical delivery systems.

Obvious Combinations & Variations

Source Patent Element
Self-emulsifying cannabidiol composition with specific surfactant ratios
PTD Variation
Novel surfactant blends optimized for gut-brain axis interaction
Obviousness Reasoning
A PHOSITA would recognize that surfactant optimization is a routine design choice in pharmaceutical formulation, with predictable methods for enhancing bioavailability through molecular engineering
Source Patent Element
Cannabidiol composition for treating neurological conditions
PTD Variation
Integration of neurostimulation therapies with cannabidiol delivery
Obviousness Reasoning
Combining pharmaceutical interventions with complementary therapeutic modalities is a standard approach in neurological treatment, representing an obvious therapeutic strategy
Source Patent Element
Emulsion-based drug delivery system
PTD Variation
Wearable device for real-time pharmacokinetic monitoring
Obviousness Reasoning
The application of continuous monitoring technologies to pharmaceutical interventions is a predictable technological progression, particularly in personalized medicine approaches
Source Patent Element
Cannabidiol composition with variable administration methods
PTD Variation
Alternative administration routes including nasal spray and transdermal patch
Obviousness Reasoning
Exploring alternative drug delivery mechanisms is a standard pharmaceutical development strategy, with finite known routes of administration that would be obvious to a skilled practitioner
Source Patent Element
Cannabidiol composition for treating withdrawal symptoms
PTD Variation
Machine learning algorithms for predicting optimal dosing based on genetic profile
Obviousness Reasoning
Personalized medicine approaches utilizing genetic and historical data for treatment optimization represent a predictable technological evolution in pharmaceutical sciences
35 U.S.C. § 103 Summary: Based on the teachings of US Patent 11857678 and the disclosed variations, a person having ordinary skill in the art would find the claimed innovations obvious and lacking non-obvious inventive merit. The combination of known pharmaceutical formulation techniques with emerging personalized medicine technologies represents a predictable technological progression that does not meet the non-obviousness standard required for patent protection under 35 U.S.C. Section 103.

Original Patent Information

Patent NumberUS 11,857,678
TitleSelf-emulsifying cannabidiol formulations
Assignee(s)Benuvia Operations, LLC